Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases

Cancer Research

Volumn 60, Issue 8, 2000, Pages 2090-2094

  Zheng, Fuzhong F ^a   Kuduk, Scott D ^a   Chiosis, Gabriela ^a   Münster, Pamela N ^a   Sepp Lorenzino, Laura ^a   Danishefsky, Samuel J ^a   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANSAMYCIN DERIVATIVE; GELDANAMYCIN; HERBIMYCIN A; PROTEIN SERINE KINASE; PROTEIN TYROSINE KINASE; STEROID RECEPTOR;

ANTIMICROBIAL ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CATALYSIS; DRUG BINDING; DRUG SYNTHESIS; ENZYME DEGRADATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; DIMERIZATION; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; LACTAMS, MACROCYCLIC; PROTO-ONCOGENE PROTEINS C-RAF; QUINONES; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0034655207     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Tzahar, B., and Yarden, Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim. Biophys. Acta, 1377: 25-37, 1998.
2. Ross, J. S., and Fletcher, J. A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells, 16: 413-428, 1998.
3. Fan, Z., and Mendelsohn, J. Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol., 10: 67-73, 1998.
4. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., and Slamon, D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-over-expressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.
5. Uehara, Y., Hori, M., Takeuchi, T., and Umezawa, H. Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. Cell. Biol., 6: 2198-2206, 1986.
6. Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., and Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 91: 8324-8328, 1994.
7. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell, 89: 239-250, 1997.
8. Schneider, C. Sepp-Lorenzino, L., Nimmersgen, E., Ouerfelli, O., Danishefsky, S., Rosen, N., and Hartl, F-U. Pharmacologie shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. USA, 93: 14536-14541, 1996.
9. Mimnaugh, E., Chavany, C., and Neckers, L. M. Polyubiquitination and proteasomal degradation of the p185c-erbB2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem., 271: 22796-22801, 1996.
10. Whitesell, L., and Cook, P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol. Endocrinol., 10: 705-712, 1996.
11. Schulte, T. W., Blagosklonny, M. V., Ingui, C., and Neckers, L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J. Biol. Chem., 270: 24585-24588, 1995.
12. Miller, P., DiOrio, C., Moyer, M., Schnur, R. C., Bruskin, A., Cullen, W., and Moyer, J. D. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res., 54: 2724-2730, 1994.
13. Schnur, R. C., Corman, M. L., Gallaschun, R. J., Cooper, B. A., Dee, M. F., Doty, J. L., Muzzi, M. L., DiOrio, C. I., Barbacci, E. G., Miller, P. E., O'Brien, A. T., Morin, M. J., Foster, B. A., Pollack, V. A., Savage, D. M., Sloan, D. E., Pustilnik, L. R., and Moyer, M. P. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem., 38: 3806-3812, 1995.
14. Hartmann, F., Horak, E. M., Cho, C., Lupu, R., Bolen, J. B., Stetler, S. M., Pfreundschuh, M., Waldmann, T. A., and Horak, I. D. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. Int. J. Cancer, 70: 221-229, 1997.
15. Cutforth, T., and Rubin, G. M. Mutations in Hsp83 and cdc37 impair signaling by the sevenless receptor tyrosine kinase in Drosophila. Cell, 77: 1027-1036, 1994.
16. Jove, R., Mayer, B. J., Iba, H., Laugier, D., Poirier, F., Calothy, G., Hanafusa, T., and Hanafusa, H. Genetic analysis of p60v-src domains involved in the induction of different cell transformation parameters. J. Virol., 60: 840-848, 1986.
17. Jove, R., Garber, E. A., Iba, H., and Hanafusa, H. Biochemical properties of p60v-src mutants that induce different cell transformation parameters. J. Virol., 60: 849-857, 1986.
18. Chavany, C., Mimnaugh, E., Miller, P., Bitton, R., Nguyen, P., Trepel, J., Whitesell, L., Schnur, R., Moyer, J., and Neckers, L. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J. Biol. Chem., 271: 4974-4977, 1996.
19. Wang, L. M., Kuo, A., Alimandi, M., Veri, M. C., Lee, C. C., Kapoor, V., Ellmore, N., Chen, X. H., and Pierce, J. H. ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proc. Natl. Acad. Sci. USA, 95: 6809-6814, 1998.